Since U.S. FDA approval of the multiple myeloma drug with the funny name, "daratumumab," in late 2015, blood bankers have had a lot to learn and still can be confused about the drug's effect on testing. Dr. Kaufman is an international expert on this topic, and he helps clear the mysteries of DARA with practical strategies you can learn right away!
